Joshua TarnoffDirector, President and Chief Executive Officer
Mr. Tarnoff joined Complexa in 2011 as Director, President and Chief Executive Officer. Mr. Tarnoff brings nearly 30 years of pharmaceutical experience to his leadership of Complexa. He has built and led businesses within large pharma and biotechnology companies, as well as multiple early stage start-ups. His most recent roles include serving as CEO of JDP Therapeutics, CEO of Houston Pharma (and its subsidiary Potomac Pharma), and CCO at ViroPharma. One of his many roles within large pharma was leading a $1.5 billion U.S. business unit at AstraZeneca. He is a recognized industry leader for his expertise in creating successful management teams, building start-up companies, strategic planning and corporate development. Mr. Tarnoff also has a strong record of a series of capital raises. With a career that advanced within the executive ranks of the commercial and operations side of the industry, he brings a unique set of skills that blend clinical and business development activities that lead to successful exits. Mr. Tarnoff received a bachelor’s degree in Biology from LaSalle University. He is also currently a board member of several early stage healthcare companies.
Federica F. O’BrienChief Financial Officer
Ms. O’Brien brings 30 years of financial and operational leadership for both public and private companies to Complexa. Ms. O’Brien has held a management role at multiple life science companies including Barrier Therapeutics, Cardiokine, Inc, Cervilenz Inc, and Cerecor Inc. Ms. O’Brien has been key to raising capital and readying companies for the public markets. Most recently at Cerecor, Ms. O’Brien was instrumental in a $32 million Series B financing. While at Cervilenz, in addition to raising capital, Ms. O’Brien led the expansion of the patent portfolio worldwide and was influential in obtaining CE marking and ISO 13485 certification for a women’s healthcare device. Previously, Ms. O’Brien was Chief Financial Officer of privately-held Cardiokine Inc., a biotechnology company developing compounds for the treatment and prevention of cardiovascular disease. She helped raise $87 million of venture funding and played a central role in establishing a collaboration agreement which provided Cardiokine with significant funding for development. During 2004, Ms. O’Brien was integral to the IPO at Barrier Therapeutics, where she served as Controller. Earlier in her career, she was Chief Financial Officer of Infonautics, Inc, a publicly held technology based company, and began her career in public accounting, most recently at Coopers & Lybrand (PWC).
Diane K. Jorkasky, M.D., F.A.C.P.Chief Medical Officer and Head of Development
Dr. Jorkasky is a highly regarded medical scientist and researcher in the pharmaceutical industry with a broad background across research and all phases of clinical development in every therapeutic area. She has played a seminal role in developing nitro-fatty acid signaling technology for treatment of inflammatory, fibrotic and metabolic diseases. She also sits on the Board of Directors of Tengion Inc., a regenerative medicine company, and Q Therapeutics, a CNS regenerative medicine company, as well as the Strategic Advisory Board of BioMotiv. Her broad experience includes positions as Head of Development and Chief Medical Officer at Endo Pharmaceuticals, with involvement in the development of drugs, devices and generics, and Aileron Therapeutics in Cambridge, Massachusetts. Prior to these appointments she had been at Pfizer in New London, CT where she had held several leadership positions in development, with the most recent being Vice President of Global Clinical Research Operations. She led the complete alignment of the three Pfizer Clinical Research Units, located in the US, Europe and Asia, which led to being awarded certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry to achieve such a recognition. Dr. Jorkasky has been vice president of Clinical Pharmacology at SmithKline Beecham, chief of the renal division at Presbyterian Medical Center and faculty member at the University of Pennsylvania School of Medicine, where she had received her medical degree and did her nephrology fellowship. Dr. Jorkasky is a member of the Connecticut Academy of Science and Technology. She has been recognized by the Connecticut Women’s Hall of Fame for her scientific leadership and mentoring of young women and the Connecticut Council on Technology for her leadership in driving the creative technological advances in Pfizer’s clinical research units. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology. She has been on the faculties of UCSF, Yale, Penn and Uniformed Service of Health Sciences Medical Schools. She has published over 100 peer review articles and teaches internationally on drug development. Recently Dr. Jorkasky was selected to be a Woodrow Wilson visiting fellow. The College of Wooster, where she obtained her undergraduate degree in chemistry, has honored her with the Distinguished Graduate award in 2013.